LAS VEGAS — In this Healio Video Perspective from Clinical Trials at the Summit, Michael A. Singer, MD, shares the results of a phase 2a trial investigating ANXV, a phosphatidylserine blocker designed to treat retinal vein occlusion.
The 13 patients who completed the trial were given five intravenous treatments of ANXV (Annexin Pharmaceuticals) over 7 days. Approximately 62% of patients did not require a rescue anti-VEGF injection throughout the 4-month trial. Thirty-eight percent required only one anti-VEGF rescue, Singer told Healio.
“It had rapid, long-term, durable effects,” he said.